Box-Elder Allergy Shots: The Maple That Matters in the Midwest and Western US
Box-elder allergy shots target Acer negundo — the only fully dioecious, wind-pollinated maple, clinically more important than any other Acer species. Dales et al. (Int Arch Allergy Immunol 2008) documented that box-elder/maple pollen counts correlate with severe asthma hospitalization rates in Canadian cities, ranking it alongside willow and shagbark hickory in symptom severity. No FDA-standardized extract and no SCIT RCT exists for A.
About Curex’s SCIT program
Curex’s at-home allergy shots (SCIT) are coming soon and focus on the most common environmental allergens:
- • Pollens — tree, grass, weed & ragweed
- • Pet dander — cat & dog
- • Dust mites
- • Molds — Alternaria & mold mix
Box-Elderis covered here for general education and may not be part of Curex’s current treatment set. Join the waitlist and our care team will help confirm your options.
Box-Elder Allergy Immunotherapy: How It Works
Allergy immunotherapy is the only long-term treatment that re-trains the immune system to stop overreacting to box-elder — rather than just masking symptoms with antihistamines or steroids. By gradually exposing the body to controlled doses of box-elder allergen, immunotherapy shifts the underlying allergic response and produces relief that often outlasts treatment by 7–10 years.
There are two evidence-based forms of box-elder immunotherapy used today, both built on the same desensitization principle but delivered very differently.
of sustained relief after a complete immunotherapy course — the only allergy treatment with proven long-term effect after stopping.
Allergy Shots (SCIT)
Weekly injections of box-elder extract in a clinic, escalating over 3–6 months until a maintenance dose is reached. Continued monthly for 3–5 years. Longest clinical track record for box-elder allergy.
- Strongest evidence base for severe and polysensitized patients
- Covered by most insurance plans
- Requires 50–100+ in-person clinic visits across the full course
- Or at home with no clinic visits— Curex’s Virtual Shot Room model delivers the same SCIT program with live video supervision by trained Curex clinical staff for the first injection from each new vial or concentration and restarts after gaps or reactions.
Allergy Drops / Tablets (SLIT)
Daily drops or dissolvable tablets containing box-elder extract, held under the tongue at home. Same desensitization principle, delivered without injections. WHO-recognized as an effective form of allergy immunotherapy since 2001.
- Taken at home — no weekly clinic trips, no needles
- Lower systemic reaction rate than allergy shots
- Curex offers prescription box-elder immunotherapy drops with allergist oversight
The rest of this page goes deep on allergen-specific immunotherapy with shots — protocol, efficacy data, side effects, and cost. If you’d rather skip the clinic and treat box-elder allergy with at-home drops, see how Curex sublingual immunotherapy compares below.
What is Box-Elder?
The biology, taxonomy, and clinical fingerprint of Box-Elder — the foundation of how SCIT targets it.
Acer negundo is the only fully dioecious maple — all-male trees release wind-dispersed pollen across the late April–early May peak without the insect-pollination buffer that limits aeroallergen output from other maple species. The rugulate-undulating pollen sexine is a palynological identifier.
- Scientific name
- Acer negundo L.
- Family
- Sapindaceae (formerly Aceraceae; APG IV reclassification)Maple family
- Type
- Dioecious wind-pollinated spring tree pollen — the outlier maple
- Native to
- Eastern and central North America; naturalized along watercourses through western US, Canada, and parts of Europe
- Allergen proteins
- No WHO/IUIS-named allergen for Acer negundo (no Ace n allergen at allergen.org as of May 2026)Multiple IgE-binding bands by Western blot in box-elder pollen extractsPan-tree pollen cross-reactive proteins (profilins, polcalcins) likely present but uncharacterized for Acer
- Particle size
- 22–51 × 20–36 µm; distinctive rugulate-undulating sexine morphology (palynological signature)
- Avoidance difficulty
- Nearly impossible
How Box-Elder Allergy Presents
Symptoms by body system — useful for distinguishing Box-Elder sensitivity from overlapping allergies and infections.
Respiratory
- Spring rhinitis peaking during late April–early May box-elder pollen release
- Asthma exacerbations correlated with box-elder/maple pollen counts (Dales et al. 2008 — asthma hospitalization correlation in Canadian cities)
- Nasal congestion and sneezing from wind-dispersed pollen along watercourses and urban tree corridors
- Chronic sinusitis flares during extended box-elder season in heavily sensitized patients
Ocular
- Allergic conjunctivitis during late April–May box-elder pollen peak
- Eye itching, tearing, and redness during high-pollen-count spring days
- Periorbital swelling in heavily sensitized patients along box-elder-lined watercourses
Dermal
- Atopic dermatitis flares during spring box-elder pollen season
- Rare urticaria in highly sensitized individuals with direct high-pollen exposure
- Skin symptoms typically less prominent than respiratory and ocular presentation
Systemic
- Severe asthma with ER visits and hospitalizations during box-elder peak in sensitized asthmatic patients (Dales 2008 data)
- Fatigue and cognitive impairment from seasonal spring allergic disease
- Missed work and school during heavy late-April box-elder pollen events in the Midwest and riparian West
Box-elder is the maple I prescribe for first. It's dioecious — all-male trees dumping wind-borne pollen the way no other maple does — and the asthma hospitalization data from Dales 2008 made me change how I rank Sapindaceae severity. The asymmetric cross-reactivity is clinically real: box-elder patients react to red and silver maple, but not all red-maple patients will be fully captured by a box-elder-only prescription. That's why most Midwest allergists use the combined maple-boxelder mix.
When & Where Box-Elder Peaks
Allergen intensity by month and by state. Useful for timing SCIT start dates and travel planning.
12-Month Intensity
Peak: late April through mid-May (box-elder dominant; later than true maples which flower March–April)· ~6 weeks of significant box-elder pollen exposure; overlapping with late true maple season in April
US Exposure Map
12 high-intensity statesExposure intensity by state (text version)
- ME:
- Low
- VT:
- Low
- NH:
- Low
- WA:
- Moderate
- MT:
- Moderate
- ND:
- High
- MN:
- High
- WI:
- High
- MI:
- High
- NY:
- Moderate
- MA:
- Low
- OR:
- Moderate
- ID:
- Moderate
- WY:
- Moderate
- SD:
- High
- IA:
- High
- IL:
- High
- IN:
- High
- OH:
- High
- PA:
- Moderate
- NJ:
- Moderate
- CT:
- Low
- RI:
- Low
- CA:
- Moderate
- NV:
- Low
- UT:
- Moderate
- CO:
- Moderate
- NE:
- High
- MO:
- High
- KY:
- Moderate
- WV:
- Moderate
- VA:
- Moderate
- MD:
- Moderate
- DE:
- Low
- AZ:
- Low
- NM:
- Low
- KS:
- High
- AR:
- Low
- TN:
- Moderate
- NC:
- Moderate
- SC:
- Low
- OK:
- Low
- LA:
- Low
- MS:
- Low
- AL:
- Low
- GA:
- Low
- TX:
- Low
- FL:
- Low
- AK:
- Low
- HI:
- Low
What Box-Elder Cross-Reacts With
Patients sensitized to one allergen often react to others sharing similar proteins. This map shows the documented molecular overlaps.
Box-elder shows asymmetric intra-Acer cross-reactivity — sensitized patients react broadly to true maples, but the reverse is incomplete. This asymmetry defines the mix rationale and distinguishes box-elder from red maple as the more clinically 'primary' sensitizer.
Combined Acer prescription exploiting high but incomplete intra-Acer cross-reactivity; box-elder is dominant component
Is SCIT Right for Your Box-Elder Allergy?
Answer 5 questions to assess whether box-elder specifically — versus the combined maple-boxelder mix — is the appropriate SCIT target for your spring tree allergy.
How severe are your late-April to May spring pollen symptoms specifically?
The Box-Elder SCIT Protocol
Box-elder SCIT follows standard non-standardized tree pollen build-up. Because box-elder shows asymmetric cross-reactivity with true maples, many allergists prescribe the combined maple-boxelder preparation to ensure coverage of both exposure components.
Weekly escalation from the most dilute starting concentration (typically 1:100,000 w/v for non-standardized tree extracts) to maintenance dose over 6–8 months. Pre-seasonal initiation in summer or autumn before the late-April/May season is preferred. Consider spring pre-season boosting if maintenance doses are missed during the off-season. Box-elder's high clinical severity (Dales 2008 asthma correlation) supports maintaining the build-up schedule through the winter to reach maintenance before the late-April peak.
Ongoing maintenance injections continue for 3–5 years on a schedule set by the prescribing allergist. Most patients report meaningful spring symptom reduction during their second season of treatment. The absence of box-elder-specific RCT data means clinical response assessment at each annual visit guides continuation decisions.
After completing the full course, symptom benefit often persists for years, similar to other inhalant SCIT programs. Re-evaluation of sensitization pattern and symptom burden guides the decision to extend, maintain, or discontinue.
Extract Concentration Ladder
You progress through each vial during build-up. Concentration increases ~10x per step.
What the Research Shows for Box-Elder SCIT
No published SCIT RCT exists for box-elder pollen. The clinical case for treatment rests on documented asthma hospitalization correlation with maple/box-elder pollen counts and general tree SCIT principles.
- Box-elder/maple pollen correlation with asthma hospitalizations (Dales 2008)65%Dales RE et al., Int Arch Allergy Immunol 2008;146:241 — box-elder/maple counts correlated with severe asthma ER visits and hospitalizations in 6 Canadian cities
- Box-elder SCIT-specific RCT evidence0%No SCIT RCT identified for Acer negundo through May 2026 — Cox 2011 JACI Practice Parameter; Greenhawt 2023 JTF update
- Climate trend: Midwest pollen integral increase (Anderegg 2021 PNAS)21%Anderegg WRL et al., PNAS 2021;118:e2013284118 — 21% Midwest pollen-integral increase; box-elder season lengthening
Box-elder SCIT lacks species-specific RCT evidence despite its documented asthma-hospitalization significance (Dales 2008). Clinical practice is guided by general tree SCIT principles (Cox 2011 JACI Practice Parameter), the asymmetric cross-reactivity evidence justifying the combined maple-boxelder approach, and the growing pollen season concern from Anderegg 2021 PNAS data. Patients should understand the extrapolated nature of the evidence before committing to a 3–5 year course.
Ready to skip the surprise bills?
At-home allergy shots (SCIT) are designed by board-certified allergists. See the listed SCIT plan rate in our pricing record and request a quote for eligibility, initiation and total care costs.
- MD-ledBoard-certified allergists
- QuoteTotal care estimate
- 50K+Patients treated
- HSA/FSAEligible
Box-Elder SCIT Side Effects
Box-elder SCIT side effects are consistent with general non-standardized tree pollen SCIT — local reactions are the most common adverse event.
Local reactions
4 documented| Reaction | Rate | Severity |
|---|---|---|
Injection-site swelling and erythema | Rate 25–50% | Mild |
Injection-site itching | Rate 20–40% | Mild |
Large local reaction (>5 cm) More variable with non-standardized extracts | Rate 5–15% | Moderate |
Delayed local reaction (4–8 hours) | Rate 10–20% | Mild |
Systemic reactions
4 documented| Reaction | Rate | Severity |
|---|---|---|
Rhinitis/conjunctivitis flare | Rate 1–2% | Mild |
Urticaria | Rate 0.3–0.8% | Moderate |
Asthma exacerbation post-injection Pre-injection asthma assessment recommended given Dales 2008 asthma severity correlation | Rate 0.5–1% | Moderate |
Systemic anaphylaxis | Rate <0.1% | Severe |
All SCIT requires a 30-minute observation period with clinic-based epinephrine. Asthma control should be confirmed before each injection given box-elder's documented asthma severity correlation. Non-standardized extract variability means local reaction rates are less predictable than with FDA-standardized allergens.
SCIT vs Alternatives for Box-Elder
For box-elder allergy, the treatment options span combined Sapindaceae SCIT, at-home allergy shots, avoidance, and pharmacotherapy — all against the backdrop of no species-specific RCT evidence. Curex at-home IgE testing covers box-elder as a distinct panel item, critical given its outsized clinical role within the maple family and the need to confirm box-elder (not just generic tree pollen) as the primary sensitizer before selecting the appropriate SCIT preparation.
| Criterion | Box-Elder/Maple SCITBest | Curex At-Home Shots | Avoidance | Pharmacotherapy |
|---|---|---|---|---|
| Effectiveness | Moderate (extrapolated) | Moderate (extrapolated) | Partial only | Controls symptoms |
| 5-yr cost | $3,500–$8,000 | program quote required at home | $0–$300/yr | $500–$2,000/yr |
| Duration | 3–5 years | 3–5 years | Ongoing | Indefinite |
| Convenience | Weekly clinics 6 mo | Weekly self-injection at home | Lifestyle changes | Daily medication |
| Safety | 30-min observation | Video-supervised dosing; epi on hand | Safest | Generally safe |
| Evidence level | No species-specific RCT | Limited tree-pollen RCT data | Reasonable | Standard of care |
Box-Elder/Maple SCITBest
Curex At-Home Shots
Avoidance
Pharmacotherapy
Box-elder-anchored SCIT (typically as combined maple-boxelder prescription) is the standard clinical approach for confirmed Acer sensitization. Curex at-home IgE testing covers box-elder as a distinct panel item — critical given its outsized clinical role — and our at-home allergy shots with pricing confirmed in a current program quote let patients treat the actual driver allergen from home: a USP <797> sterile-compounded serum, a video-supervised the first injection from each new vial or concentration, a prescribed epinephrine auto-injector confirmed on hand, and gradual allergist-overseen escalation timed to the late-April peak.
What Box-Elder SCIT Actually Costs
Most major insurers cover tree pollen SCIT when prescribed by a board-certified allergist with documented IgE sensitization and adequate symptom burden. Prior authorization is commonly required; patients should verify coverage before initiating treatment.
Cost range varies by deductible, co-insurance, and clinic.
Verify these codes with your insurer to confirm coverage.
See the listed Environmental Allergy Shots Plan rate, commercial terms dated 2026-10-12; consultations are included without copay. Confirm availability, eligibility, other included services, testing, any in-person care, insurance responsibility and billing cadence in your written quote before enrolling.
Join the waitlistStop guessing about your box-elder allergy. Get a plan.
Take Curex’s 3-minute allergy quiz. A board-certified allergist will review your symptoms and recommend the right immunotherapy path for you — shots or drops.
Free quiz · Board-certified allergists · 50,000+ patients treated · HSA/FSA eligible
Box-Elder SCIT — Frequently Asked
Quick answers to the questions patients ask most before starting treatment.
Box-elder (Acer negundo) is the only fully dioecious maple — it produces completely separate male and female trees, and the male trees release large quantities of wind-dispersed pollen without the insect-pollination buffer that reduces airborne output from monoecious maple species. Red maple, silver maple, and sugar maple are primarily monoecious (both flower types on the same tree) and partially insect-pollinated, meaning a significant fraction of their pollen never becomes airborne. Box-elder's obligate wind-pollination strategy (documented by Bawa Annu Rev Ecol Syst 1980; Renner & Ricklefs Am J Bot 1995) results in pollen release optimized for atmospheric dispersal, creating higher ambient pollen concentrations than other Acer species at equivalent tree density. Additionally, box-elder's asymmetric cross-reactivity — box-elder sensitized patients react broadly to other Acer, but reverse cross-reactivity is incomplete — suggests its allergen profile may be particularly potent.
Box-elder (Acer negundo) is one of the most widely distributed North American trees — native to the eastern and central US, it has naturalized along watercourses through the Rocky Mountains to the Pacific Coast. The US Forest Service Silvics of North America documents its presence in virtually every state except the Deep South and Alaska. In the Midwest (Iowa, Illinois, Indiana, Missouri, Minnesota, Nebraska, Kansas), box-elder is a dominant riparian tree with high pollen loads tracked by National Allergy Bureau (NAB) stations. In the western US, it follows major river corridors (Missouri, Platte, Colorado, Sacramento) creating unexpected high-exposure zones in arid regions not typically associated with spring tree allergy. If you live near rivers, streams, or in the Midwest or Mid-Atlantic, the late April–May box-elder peak likely represents your single highest spring tree pollen exposure event.
Both single-species box-elder SCIT and combined maple-boxelder SCIT are available as non-standardized preparations in US allergy practices. The choice depends on your specific sensitization pattern. If testing shows strong box-elder positivity with weaker or absent true maple reactions, a box-elder-dominant preparation may be appropriate. If testing shows significant reactivity to both box-elder and red or silver maple, the combined preparation provides broader coverage. Given box-elder's asymmetric cross-reactivity — where box-elder sensitized patients tend to react broadly to other Acer species but true-maple patients don't always react equivalently to box-elder — most Midwest and Mid-Atlantic allergists prescribe the combined maple-boxelder mix to ensure coverage. A board-certified allergist can interpret your testing pattern and recommend the appropriate preparation.
Anderegg et al. (PNAS 2021, e2013284118) documented that North American pollen integrals have increased approximately 21% on average over the past three decades, with spring seasons starting earlier and summer seasons lasting longer. Box-elder and maple are among the spring tree species specifically noted for seasonal extension in the Midwest — the region where box-elder has its highest concentration and allergic burden. For box-elder sensitized patients in the Midwest, this means the late-April/May peak may be arriving earlier in recent years, and the overall pollen season may be longer than it was a decade ago. This trend strengthens the clinical case for immunotherapy as a long-term solution over annual pharmacotherapy for patients who are getting worse each spring — and Curex now delivers that immunotherapy as at-home allergy shots with pricing confirmed in a current program quote, with a video-supervised first dose and allergist oversight throughout.
Box-elder SCIT does not reliably cross-protect against willow (Salicaceae) or sycamore (Platanaceae) allergies — these are botanically unrelated trees with different allergen profiles. While box-elder and willow are ranked at comparable clinical severity in regional aerobiology studies, and both are common in riparian habitats, their pollen proteins are largely distinct. Sycamore (London plane in urban settings) has its own characterized allergens (Pla a 1, Pla a 2, Pla a 3). Willow (Salix) and sycamore have no documented significant cross-reactivity with Acer. If you're reacting to multiple spring tree species — box-elder, willow, sycamore, and oak all peaking in roughly the same April–May window in the Midwest and East — your allergist may prescribe a multi-species spring tree mix covering each family in separate vials, rather than relying on any one species to provide cross-protection for the others.
Yes — box-elder SCIT is appropriate for children with confirmed Acer negundo sensitization and inadequately controlled spring symptoms, typically starting at age 5 or older. The asthma-hospitalization data from Dales 2008 is particularly relevant for pediatric patients, as it documents that box-elder/maple pollen is a genuine pediatric asthma trigger — not just a nuisance allergy. AAAAI/ACAAI Practice Parameter guidelines support tree pollen SCIT in appropriate pediatric candidates with documented sensitization and inadequate pharmacotherapy control. Important considerations for children include starting the 6–8 month build-up before the school year to reach maintenance by the spring season, the long 3–5 year commitment, and the need for the child to be able to tolerate injections and communicate any adverse reactions during the 30-minute post-injection observation. Reassuringly, a large safety study of self-administered allergen immunotherapy (Schaffer et al., 2015) found that across 23,614 patients giving 2,021,600 injections, the systemic reaction rate was just 0.16% per patient with no fatalities — lower than the 3%–14% typically seen with office-based shots. Note: the Curex at-home pilot is currently open to patients age 12 and older; pediatric patients require a trained adult caregiver physically present for every injection.
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.
Questions about Curex itself?
Straight answers about the company, the evidence, what patients report, and what it costs — including the parts that are not flattering.